Murdo Gordon gets Chief Commercial Officer role at Bristol-Myers Squibb
pharmafile | June 21, 2016 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BMS, Bristol-Myers Squibb, chief commercial officer
Bristol-Myers Squibb (NYSE: BMY) has announced the appointment of Munro Gordon as executive vice president and chief commercial officer, effective from June 21.
The newly created position will see Gordon responsible for leading the execution of commercial strategy across the world. He will report to BMS chief executive, Giovanni Caforio, and remain a member of the leadership team.
Caforio comments: “Murdo has demonstrated tremendous success driving commercial excellence at Bristol-Myers Squibb, and built strong relationships with our markets across the world. Murdo has made significant contributions to our success in immune-oncology and Eliquis, and I am confident his leadership will help drive continued growth and deliver our medicines to more patients faster.”
Gordon joined the company in 1989 and spent the first 14 years there in Canada, holding roles of increasing seniority in sales and marketing. Most recently, Gordon held the role of head of worldwide markets at BMS. He is also a member of the board of directors of RWJBarnabas Health and received a BSc in Cell and Molecular Biology from Concordia University, Montreal.
Related Content

Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …

BMS shares new research and development plans at the company’s R&D day
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …






